Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label conversion/maintenance study of enarodustat versus recombinant human erythropoietin in anemia of chronic kidney disease in maintenance hemodialysis patients
CTR20232186Phase 3Active
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enarodustat, erythropoietin in Uraemic Anaemia, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Jul 2023; status: active.
02
Drugs
enarodustaterythropoietin
03
Conditions
Uraemic Anaemia
Beyond the preview
Go deeper on CTR20232186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232186.